Journal article
Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men
Prostate cancer and prostatic diseases, Vol.25(2), pp.180-186
02/01/2022
DOI: 10.1038/s41391-022-00507-8
PMID: 35246608
Abstract
Several liquid biomarker tests have been developed to account for the limitations of prostate specific antigen (PSA) screening prior to prostate biopsy. African ancestry is an established risk factor for prostate cancer (PCa) and must be particularly considered when evaluating patients with liquid biomarkers. While multiple tests have been developed over decades of exploration, recent advances can help patients and physicians incorporate data into a broader clinical context.
We sought to review currently available liquid biomarker tests in a practical, clinically directed fashion with particular focus on performance in men with African ancestry. We reviewed discovery and validation studies and highlight important considerations for each test.
We discuss the advantages and limitations of percent free PSA, Prostate Health Index, Progensa® PCA3, ExoDx® Prostate Test, SelectMDx®, 4Kscore® Test, and Mi-Prostate Score and summarize salient studies on their use. A literature review of evidence specifically for men with African ancestry was conducted and available studies were summarized.
Liquid biomarkers can be useful tools for aiding in risk stratification prior to prostate biopsy. Use of such tests should be individualized based on a thorough knowledge of supporting evidence and the goals of the patient and physician. Further study should prioritize evaluation of such biomarkers in men with African ancestry.
Details
- Title: Subtitle
- Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men
- Creators
- Grant M Henning - Washington University in St. LouisGerald L Andriole - Washington University in St. LouisEric H Kim - Washington University in St. Louis
- Resource Type
- Journal article
- Publication Details
- Prostate cancer and prostatic diseases, Vol.25(2), pp.180-186
- DOI
- 10.1038/s41391-022-00507-8
- PMID
- 35246608
- NLM abbreviation
- Prostate Cancer Prostatic Dis
- ISSN
- 1365-7852
- eISSN
- 1476-5608
- Language
- English
- Date published
- 02/01/2022
- Academic Unit
- Urology
- Record Identifier
- 9984949457102771
Metrics
4 Record Views